Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.63 |
| ▸ | CA12 | O43570 | 4/20 | 0.63 |
| ▸ | CA1 | P00915 | 4/20 | 0.63 |
| ▸ | CA2 | P00918 | 4/20 | 0.63 |
| ▸ | CA4 | P22748 | 4/20 | 0.63 |
| ▸ | CA9 | Q16790 | 4/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839246 | 1.00 | PTGES (0.63) | PTGESALOX5PTGS2CA12CA1 | |
| SCHEMBL861693 | 0.96 | CA12 (0.64) | PTGESALOX5PTGS2CA12CA1 | |
| SCHEMBL14351089 | 0.92 | CA12 (0.56) | PTGESALOX5PTGS2CA12CA1 | |
| SCHEMBL14351094 | 0.88 | CA12 (0.54) | PTGESALOX5PTGS2CA12CA1 | |
| SCHEMBL10147688 | 0.88 | CA12 (0.50) | PTGESALOX5PTGS2CA12CA1 | |
| SCHEMBL14728152 | 0.87 | PTGS2 (0.53) | PTGESALOX5PTGS2CA12CA1 | |
| SCHEMBL4243296 | 0.85 | PTGS2 (0.75) | PTGS2PTGS1HRH4 | |
| SCHEMBL13290328 | 0.84 | PTGS2 (0.45) | PTGESALOX5PTGS2CA12CA1 | |
| SCHEMBL10147685 | 0.84 | CA12 (0.52) | PTGESALOX5PTGS2CA12CA1 | |
| SCHEMBL13286862 | 0.81 | PTGS2 (0.64) | PTGS2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865130-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2013-02-28 | — | — | US | disclosed |
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | PTGES 8/4885ALOX5 83/4885PTGS2 1/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | PTGES 5/4885ALOX5 43/4885PTGS2 2/4885 |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | PTGES 8/4885ALOX5 83/4885PTGS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.